Our imaging agent candidate – GlioStem® Surgery
GlioStem® Surgery is currently being developed for use during glioma brain tumor surgery to detect and illuminate glioma stem cells. Emerging research suggests that failure to target glioma stem cells, rather than the inability to remove tumors through surgery, radiation, or chemotherapy, explains the poor survival of malignant glioma patients. GlioStem® Surgery is intended to enable neurosurgeons to detect and surgically remove glioma stem cells during fluorescence-guided surgery, with a particular focus on the tumor margin, where tumor recurrence often occurs.
GlioStem® Surgery is currently in pre-clinical phase, with the aim of progressing into Phase 1 clinical development. Accordingly, GlioStem® Surgery is not yet commercially available.
For further information, please contact us by e-mail or by filling out this form.
Glioma stem cells are associated with tumor initiation, treatment resistance and recurrence, making them an important target in glioblastoma.